MARKET

OPGN

OPGN

Opgen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3775
+0.0150
+4.14%
Closed 18:11 05/25 EDT
OPEN
0.3600
PREV CLOSE
0.3625
HIGH
0.3939
LOW
0.3551
VOLUME
146.96K
TURNOVER
--
52 WEEK HIGH
3.720
52 WEEK LOW
0.3100
MARKET CAP
17.58M
P/E (TTM)
-0.4525
1D
5D
1M
3M
1Y
5Y
OpGen Announces Publication Of Results From Major Clinical Study Using Unyvero Hospitalized Pneumonia Panel In The Lancet Respiratory Medicine
208 patients enrolled in a prospective, randomized, controlled, multicenter, interventional trial Unyvero reduced the use of inappropriate antibiotic therapy by 45%, shortened inappropriate antibiotic therapy by
Benzinga · 28m ago
OpGen, Inc. (OPGN) Reports Q1 Loss, Lags Revenue Estimates
OpGen, Inc. (OPGN) delivered earnings and revenue surprises of 6.25% and 55.24%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/12 21:35
Recap: OpGen Q1 Earnings
OpGen (NASDAQ:OPGN) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings OpGen reported in-line EPS of $-0.15 versus an estimate of $-0.15.
Benzinga · 05/12 21:07
OpGen Q1 EPS $(0.15), Inline, Sales $470.00K Miss $1.17M Estimate
OpGen (NASDAQ:OPGN) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate. This is a 37.5 percent increase over losses of $(0.24) per share from the same period last year. The company
Benzinga · 05/12 20:52
OpGen GAAP EPS of -$0.15 beats by $0.01, revenue of $0.47M misses by $0.58M
OpGen press release (NASDAQ:OPGN): Q1 GAAP EPS of -$0.15 beats by $0.01. Revenue of $0.47M (-43.4% Y/Y) misses by $0.58M.
Seekingalpha · 05/12 20:37
BRIEF-OpGen Reports Q1 2022 Financial Results
reuters.com · 05/12 20:19
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/12 12:42
OpGen Q1 2022 Earnings Preview
OpGen (OPGN) is scheduled to announce Q1 earnings results on Thursday, May 12th, after market close. The consensus EPS Estimate is -$0.16 and the consensus Revenue Estimate is $1.05M (+26.5%
Seekingalpha · 05/11 21:35
More
No Data
Learn about the latest financial forecast of OPGN. Analyze the recent business situations of Opgen through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average OPGN stock price target is 3.000 with a high estimate of 3.000 and a low estimate of 3.000.
High3.000
Average3.000
Low3.000
Current 0.3775
EPS
Actual
Estimate
-0.40-0.30-0.20-0.10
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Institutional Holdings
Institutions: 38
Institutional Holdings: 4.25M
% Owned: 9.13%
Shares Outstanding: 46.56M
TypeInstitutionsShares
Increased
8
84.05K
New
3
130.57K
Decreased
7
852.72K
Sold Out
6
344.54K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.55%
Pharmaceuticals & Medical Research
+0.02%
Key Executives
Non-Executive Chairman/Independent Director
William Rhodes
Chief Executive Officer/Director
Oliver Schacht
Chief Financial Officer
Albert Weber
Chief Operating Officer
Johannes Bacher
Independent Director
Mario Crovetto
Independent Director
R. Donald Elsey
Independent Director
Prabhavathi Fernandes
No Data
No Data
About OPGN
OpGen, Inc. (OpGen) is a precision medicine company that uses molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information of products and services for global healthcare settings to guide clinicians with information about infections, improve patient outcomes and decrease the spread of infections caused by multidrug-resistant organisms (MDROs). The Company’s molecular diagnostics and informatics product candidates and services combine its Unyvero and Acuitas molecular diagnostics and Ares Genetics’ database and the Acuitas Lighthouse informatics platform.The molecular diagnostic tests provide microbial identification and antibiotic resistance gene information. The Acuitas Lighthouse informatics systems are cloud-based informatics offerings, which are designed to combine clinical lab test results with patient.

Webull offers kinds of OpGen Inc stock information, including NASDAQ:OPGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OPGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OPGN stock methods without spending real money on the virtual paper trading platform.